ANI Pharmaceuticals beats top-line and bottom-line estimates; narrows FY26 outlook
Read original article on Breaking News on Seeking Alpha →Related news
-
Sarepta misses on the bottom line but raises lower end of 2026 revenue guidance
Business
Corporate
United States
-
Trump-backed critical minerals deals under pressure after Democratic sweep - Bloomberg
Business
United States
-
Icu Medical signals 2026 results toward high end of $415M-$435M EBITDA and $8.60-$9 EPS range as logistics consolidation normalizes
Business
Corporate
United States
-
Sempra signals 20% increase in Oncor’s $47.5B capital plan while guiding to high end of $4.80-$5.30 2026 adjusted EPS range
Business
Corporate
United States
-
Krispy Kreme outlines $1.35B-$1.4B 2026 net revenue as it targets 2%-4% systemwide sales growth
Business
Corporate
United States
- Organogenesis Holdings GAAP EPS of -$0.25 misses by $0.07, revenue of $45.4M misses by $6.71M Business Corporate
- Chesapeake Utilities Non-GAAP EPS of $0.89 misses by $0.05, revenue of $195.8M beats by $9.15M Business Corporate
- Phio Pharmaceuticals GAAP EPS of -$0.36 in-line Business Corporate